FDA grants accelerated approval for ADUHELM™ as the first and onBIIB: Biogen Inc.
2021-06-07 13:00:00
FDA grants accelerated approval for ADUHELM™ as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease
BIIBCL trade ideas
Biotech and Pharma Time Is Near "Biogen to the moon"Certainly the "to the moon" for an established company like Biogen may be out of place but it makes the idea of the interest that big investors are demonstrating towards pharme and biotech companies in recent times.
From what I see on Miracle Viewer, the indicator that analyzes the market in search of the capital of big players, many of the capital of big investors are heading in these early days of June 2021 in the biotech and pharmaceutical sector.
Probably the attentions during the period of covid directed to the more IT technological field are diminishing and the capitals that flow must find a collocation in the companies and the categories of companies that have been less considered.
It’s the case of Biogen where the Marketmiracle advisor is reporting a considerable interest from the big investors but it’s also the case of other illustrious companies like $CLVS, $OTRK which I put back as connected ideas
In this case the Marketmiracle advisor gives me a signal of a small price increase (about 10%) but we are talking about a well-placed and well-run-in biotech company, an increase that will probably be reviewed in the next few hours for further leaps forward .
But let’s proceed by order
the signal provided by Marketmiracle is to go LONG on Biogen at a price of 272.55 usd for a target of 297.2232 usd or a potential increase of 9.05%
From the fundamental point of view the company seems to be underestimated by about 43% ( estimate made by analysts of sites of my reference) so actually the signal could be a good opportunity to start a phase of accumulation or trade bites and escapes.
From the graphical point of view everything comes back and I would expect a movement similar to the one I drew on the graph.
This idea is based on the signal generated by the Marketmiracle advisor whose link you can find by scrolling at the bottom of this page.
Biogen (BIIB) A Roadmap...BIIB came out a nice Gartley Pattern on 4/22.
First stop should be the $277 area as AB=CD, where I would think there will be some profit taking.
Upside targets ($290+) are shown as this evolves into a possible Deep Crab Harmonic Pattern.
Biogen needs FDA drug approval, descent earning against healthy market backdrop for this to happen.
In higher time-frames you may also have a cup and handle formation.
As usual do your own DD
S.
BIIB has incoming Golden Cross, rising past support zone?Hi. In this 1D chart I've marked an impending Golden Cross: the point where a MA 56 is very likely to cross a MA 224 upwards.
With this I've also plotted out a Resistance zone and a Support zone. The price has just entered the Resistance zone but instead of turning back this time the momentum of the Golden Cross should push it past the Resistance zone.
I've also included two example trades. One has its SL placed on the price of the Golden Cross and then given a ratio of two to make a reasonable TP.
The other has its SL placed on the top line of the Support zone and given a ratio of 1.75 to make a more conservative long position and keep the TP within a reasonable price.
Thank you. Please, if you have any thoughts or comments do leave them below and I would gladly discuss or adjust my interpretations and methods with you.
This does not constitute financial advice. Any projected prices, even if explicitly stated, are made with intent to discuss the symbol and potential interpretations. Any trades shown or mentioned are examples and neither recommendations or mandates.
BIIB: Biogen triangle breakoutBIIB has broken out of triangle triangle formation on strong signals from super guppy and MACD indicators. I expect this breakout to continue on both its solid technical's as well as the strong sentiment in regards to BIIB's potential ceiling. Two crucial stories to watch going forward are the potential appeals court reversal related to their multiple sclerosis drug patent and more importantly, the potential approval of their experimental Alzheimer's drug. I believe there is a good opportunity in the short-term with strong risk/reward. I anticipate some quick upside in the short term (5-10%) and will be happy to take profits. The longer-term picture for Biogen certainly has a ton of upside potential however, there is very significant risk. Biogen has a lot riding on the 2 drugs mentioned above and the ruling made on them has the potential to make or break the company's future. I believe once a decision is passed down we will either see price rapidly surge to $400+ or rapidly fall to $175-$220 depending on the outcome.
BIIB longRanging -> breakout -> retest -> go? We will see. I cant predict the future. Tail or fade, idc
mini downtrendits a great longterm play if you got in a while ago! id wait for the top trendline to break to get long but this is a good reward if you use a tight stop on shares. but be careful if support breaks theres no floor on this one. it could be a nasty dump. goodluck :)
Biogen INC, pharmaceutical stock that is going to runBiogen INC 22 June, we were monitoring this stock. Its been 1 month, we are still waiting for a good entry
great chart request!we are looking at 100 dollars of upside after this final top line breaks! dang thanks for the request.. on my watchlist now :) leave a like if you enjoyed my idea <3
